SecBot SecBot

TPST

Tempest Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001544227 Biotech & Drug Discovery
$0.5110 +0.00 (+0.20%)
Oct 27 4:00 PM ET · prev $0.5100
Market cap
$8.6M
Nano cap
Consensus
Buy
86% Buy or better · 7 analysts
Median target
$7.00
+1270% · range $7.00–7.00
Next earnings
Nov 3
in 6 days · EPS est. −$0.32
1 year
−95.3%
from $10.89 · Oct 28
30 days
−38.6%
from $0.8320
52-week range
$0.5100–10.89
−95% from high · low Oct 26
Avg volume 20D
273.7K
Oct 2 spike 2.27M
Short interest
312.9K
≈1.9% of shares · −48.6%
Days to cover
1.0
at average volume
Insider net
+$1.0M
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read BEARISH 11 reports · 90 days
Balance 5 bearish · 1 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 10/11 ·Next Earnings date, Nov 3, 2026
Strongest BEARISH Tempest Therapeutics' 2026 definitive proxy statement schedules a November 9, 2026 annual meeting with four…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $1.0M at an average $2.16. No open-market sales. Price is 76% below their cost.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 0 trimmed or exited.

  • AnalystsBULLISH

    6 of 7 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.350 → −$0.320 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersCOVERING

    Short interest −48.6% to 312.9K shares. 1.0 days to cover, ≈1.9% of shares.

  • TrendDOWNTREND

    40% below its 50-day average. New closing low $0.5100 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
NORTHERN TRUST CORPADD20,136$22.4K
GEODE CAPITAL MANAGEMENT, LLCADD86,990$142.7K
UBS Group AGTRIM4,533$7.4K
UBS Group AGADD17,542$50.3K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

7 analysts
Buy 86% rate it Buy or better
Strong Buy2Buy4Hold1Sell0Strong Sell0
12-month targets · 1 analysts

Price is below the lowest target. Median implies +1270%.Targets as of Oct 28, 2026.

Recent actions
DateFirmActionRating
Sep 24, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 3, 2026
Earnings date
TPST Q3 2026 Earnings After Market Close — 2026-11-03
Recent
Sep 15, 2026
Press release
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
-Transaction complements Tempest’s existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic…
Sep 11, 2026
Offering
Tempest Therapeutics Announces Up to $7.5 Million Private Placement
$2.5 million upfront with up to approximately $5 million of potential aggregate gross proceeds upon the exercise in full of warrants $2.5 million…
Aug 13, 2026
Earnings
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a…
Aug 10, 2026
Earnings date
TPST Q2 2026 Earnings After Market Close — 2026-08-10
Jul 21, 2026
Earnings
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company…

Insider ledger

Form 4
$1.0M
bought · 1 insider
$0
sold · 0 insiders
−76.3%
vs their $2.16 cost
DateInsiderTypeValue
Sep 22, 2026
Smith Nancy Freda
Director
AWARD25,000 sh
Jun 4, 2026
Richey William Drake
Director
AWARD25,000 sh
Jun 4, 2026
Yee John D.
Director
AWARD25,000 sh
Mar 31, 2026
Maestas Nicholas
Chief Financial Officer
AWARD140,000 sh
Mar 31, 2026
Trojanowski Justin
Corporate Controller
AWARD22,000 sh
Mar 24, 2026
Angel Matthew
CEO and President
BUY$500.0K
Mar 24, 2026
Angel Matthew
CEO and President
BUY231,482 sh
Mar 24, 2026
Angel Matthew
CEO and President
BUY$500.0K

Earnings setup

Estimates
Nov 3
reports in 6 days
−$0.32
EPS estimate, this quarter
+9%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.32-$0.32–-$0.32+8.6%$0.00
Next Q-$0.29-$0.29–-$0.29+25.6%$0.00
Current FY-$2.85-$2.85–-$2.85-112.7%$0.00
Next FY-$0.90-$0.90–-$0.90+25.6%$0.00

Short side

FINRA· Oct 15, 2026
312,948
shares short
-48.6%
vs prior settlement
1.0
days to cover
≈1.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 SEC
Tempest Therapeutics' 2026 definitive proxy statement schedules a November 9, 2026 annual meeting with four proposals…
DEF 14A — Impact 6/10
Oct 20, 2026 SEC
Tempest Therapeutics filed a DEFA14A (definitive additional proxy soliciting materials) reporting that its reconvened…
DEFA14A — Impact 4/10
Oct 20, 2026 SEC
Tempest Therapeutics adjourned its reconvened special meeting of stockholders on October 14, 2026, because it lacked…
8-K — Impact 3/10
Sep 22, 2026 Insider
Smith Nancy Freda was granted 25,000 shares
Director
Sep 15, 2026 Other
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
-Transaction complements Tempest’s existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery p
Sep 11, 2026 Press
Tempest Therapeutics announced a private placement of ~3.1M shares and warrants at $0.805/unit, raising ~$2.5M in…
Impact 6/10
Jun 30, 2026 Inst.
NORTHERN TRUST CORP — ADD
20,136 shares ($22.4K)
Jun 4, 2026 Insider
Richey William Drake was granted 25,000 shares
Director

SecBot reports

22 filings · 5 press releases · 3 bullish · 9 bearish · 10 neutral
All TPST filing & press-release reports (27)